×
About 126,406 results

ALLMedicine™ Hepatocellular Carcinoma Center

Research & Reviews  61,951 results

The Landscape of Cell-free HBV Integrations and Mutations in Cirrhosis and Hepatocellul...
https://doi.org/10.1158/1078-0432.CCR-21-0002
Clinical Cancer Research : an Official Journal of the Ame... Zheng B, Liu X et. al.

May 5th, 2021 - Intratumoral hepatitis B virus (HBV) integrations and mutations are related to hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown itself as a powerful non-invasive biomarker for cancer. However, the HBV integra...

Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma wi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088298
Journal of Hepatocellular Carcinoma; Ye F, Huang W et. al.

May 5th, 2021 - Early diagnostic biomarkers of hepatocellular carcinoma (HCC) are needed to distinguish hepatitis B virus (HBV) associated HCC (HBV-HCC) patients from at-risk patients. We assessed the diagnostic values of serum Integrin beta-like 1 (ITGBL1) for e...

Safety and efficacy of lenvatinib by starting dose based on body weight in patients wit...
https://doi.org/10.1007/s00535-021-01785-0
Journal of Gastroenterology; Okusaka T, Ikeda K et. al.

May 5th, 2021 - REFLECT was an open-label, phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC). Based on phase 2 study (Study 202) results, body weight-based dosing for lenva...

Impact of Psychiatric Illness on Survival among Patients with Hepatocellular Carcinoma.
https://doi.org/10.1007/s11605-021-05029-7
Journal of Gastrointestinal Surgery : Official Journal Of... Rice DR, Dalmacy D et. al.

May 5th, 2021 - Impact of Psychiatric Illness on Survival among Patients with Hepatocellular Carcinoma.|2021|Rice DR,Dalmacy D,Hyer JM,Diaz A,Tsilimigras DI,|

see more →

Guidelines  147 results

Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis,...
https://doi.org/10.1016/j.clinre.2020.101590
Clinics and Research in Hepatology and Gastroenterology; Blanc JF, Debaillon-Vesque A et. al.

Mar 29th, 2021 - This document is a summary of the French Intergroup guidelines regarding the management of hepatocellular carcinoma (HCC) published in March 2019. It is a collaborative work under the auspices of most of the French medical societies involved in th...

Hepatocellular carcinoma
https://www.nature.com/articles/s41572-020-00240-3
Nature Reviews; Llovet JM

Jan 20th, 2021 - Liver cancer remains a global health challenge, with an estimated incidence of >1 million cases by 2025. Hepatocellular carcinoma (HCC) is the most common form of liver cancer and accounts for ~90% of cases. Infection by hepatitis B virus and hepa...

Diagnostic and Prognostic Implications of Cardiac Markers for Hepatocellular Carcinoma
https://pubmed.ncbi.nlm.nih.gov/33641280/
Critical Reviews in Oncogenesis; Ghanta MK

Jan 1st, 2021 - Hepatocellular carcinoma (HC) is a malignant primary liver cancer which has poor treatment outcomes in advanced stages, and many of the HC patients present with advanced stages. The incidence of death due to HC increase as a result of ineffective ...

AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achie...
https://doi.org/10.1053/j.gastro.2020.11.051
Gastroenterology Younossi ZM, Corey KE et. al.

Dec 11th, 2020 - Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease, with global public health impact affecting more than 25% of the global population. NAFLD is associated with significant morbidity and mortality from cirrhosis, h...

Liver Cancer - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK448337/
StatPearls [Internet]; Recio-Boiles A

Nov 18th, 2020 - Hepatocellular carcinoma is the most common form of primary liver cancer in the United States with three-quarters of primary and secondary liver cancer cases. The trend for both estimated new and instances of death is increasing in parallel to the...

see more →

Drugs  17 results see all →

Clinicaltrials.gov  63,107 results

The Landscape of Cell-free HBV Integrations and Mutations in Cirrhosis and Hepatocellul...
https://doi.org/10.1158/1078-0432.CCR-21-0002
Clinical Cancer Research : an Official Journal of the Ame... Zheng B, Liu X et. al.

May 5th, 2021 - Intratumoral hepatitis B virus (HBV) integrations and mutations are related to hepatocellular carcinoma (HCC) progression. Circulating cell-free DNA (cfDNA) has shown itself as a powerful non-invasive biomarker for cancer. However, the HBV integra...

Serum Levels of ITGBL1 as an Early Diagnostic Biomarker for Hepatocellular Carcinoma wi...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088298
Journal of Hepatocellular Carcinoma; Ye F, Huang W et. al.

May 5th, 2021 - Early diagnostic biomarkers of hepatocellular carcinoma (HCC) are needed to distinguish hepatitis B virus (HBV) associated HCC (HBV-HCC) patients from at-risk patients. We assessed the diagnostic values of serum Integrin beta-like 1 (ITGBL1) for e...

Safety and efficacy of lenvatinib by starting dose based on body weight in patients wit...
https://doi.org/10.1007/s00535-021-01785-0
Journal of Gastroenterology; Okusaka T, Ikeda K et. al.

May 5th, 2021 - REFLECT was an open-label, phase 3 study comparing the efficacy and safety of lenvatinib versus sorafenib in patients with unresectable hepatocellular carcinoma (uHCC). Based on phase 2 study (Study 202) results, body weight-based dosing for lenva...

Impact of Psychiatric Illness on Survival among Patients with Hepatocellular Carcinoma.
https://doi.org/10.1007/s11605-021-05029-7
Journal of Gastrointestinal Surgery : Official Journal Of... Rice DR, Dalmacy D et. al.

May 5th, 2021 - Impact of Psychiatric Illness on Survival among Patients with Hepatocellular Carcinoma.|2021|Rice DR,Dalmacy D,Hyer JM,Diaz A,Tsilimigras DI,|

see more →

News  1,179 results

Antibiotics May Prolong PFS in HCC Patients on Immunotherapy
https://www.medscape.com/viewarticle/949665

Apr 20th, 2021 - Exposure to antibiotics 30 days before or after starting treatment with an immune checkpoint inhibitor (ICI) was associated with a benefit in progression-free survival (PFS) among patients with hepatocellular carcinoma (HCC) in an international st...

New Combo Shows Benefit Even in Patients With High-Risk HCC
https://www.medscape.com/viewarticle/949271

Apr 13th, 2021 - Updated data continue to show significant clinical benefits for patients with unresectable hepatocellular carcinoma (HCC) with the combination of the immune checkpoint inhibitor atezolizumab (Tecentriq) and angiogenesis inhibitor bevacizumab (Avas...

ASCO Announces New Advanced Liver Cancer Guidelines
https://www.medscape.com/viewarticle/946306

Feb 22nd, 2021 - New guidelines from the American Society of Clinical Oncology were released to address the treatment of advanced hepatocellular carcinoma (HCC). An unprecedented number of new agents have been approved for systemic therapy of HCC in recent years, ...

Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer
https://www.medscape.com/viewarticle/945046

Jan 31st, 2021 - Long-term follow-up data show a continued benefit for patients with advanced hepatocellular carcinoma (HCC) treated with nivolumab and ipilimumab after disease progression on sorafenib, according to investigators from the Checkmate 040 trial. At a...

TACTICS: TACE Plus Sorafenib Improves PFS in Unresectable HCC
https://www.medscape.com/viewarticle/945041

Jan 31st, 2021 - Combining transcatheter arterial chemoembolization (TACE) therapy with sorafenib improved progression-free survival (PFS), but not overall survival (OS), when compared with TACE alone in patients with unresectable hepatocellular carcinoma (HCC), f...

see more →

Patient Education  5 results see all →